[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-transplant-failure-and-rejection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-transplant-failure-and-rejection":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,72,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100293612","phase-4-allograft-dysfunction-in-heart-transplant-100293612",false,"NCT03102125","Allograft Dysfunction in Heart Transplant","Defining Mechanisms for Cardiac Allograft Dysfunction to Improve Allograft Longevity and Survival in Heart-Transplant Patients","Inclusion Criteria:\n\n* Age greater than or equal to 18 years old.\n* At least three months status post heart transplantation.\n\nExclusion Criteria:\n\n* Biopsy proven acute rejection episode in the past 3 months.\n* Patients with symptoms or signs of acute myocardial ischemia or recent acute coronary syndrome in the past 3 months.\n* Uncontrolled obstructive ventilatory disease including asthma and COPD.\n* History of generalized tonic-clonic seizures.\n* Second or third degree AV nodal block.\n* Sinus node dysfunction.\n* Contraindications to MRI including cardiovascular implantable electronic devices.\n* Renal dysfunction with an estimated GFR less than 30 mL\u002Fmin\u002F1.73m2.\n* Prior adverse reaction to either regadenoson or gadolinium contrast. Prior adverse reaction to adenosine or dipyridamole will be assessed on a case-by-case basis.\n* Systolic blood pressure greater than 180 or less than 85 mmHg.\n* Diastolic blood pressure greater than 120 or less than 40 mmHg.\n* Resting heart rate greater than 120 or less than 45 beats per minute. - Severe claustrophobia.","ALL","18 Years",{"count":19,"type":20},376,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The investigators will evaluate for early evidence of cardiac allograft dysfunction by cardiac MRI and single cell sequencing to determine underlying molecular and macroscopic causes.",[26],"Heart Transplant Failure and Rejection",[28,29,30],"heart transplant","acute graft rejection","chronic graft rejection","RECRUITING","2026-04-27",{"date":34,"type":35},"2026-05-01","ACTUAL",{"date":37,"type":35},"2019-10-01",{"date":39,"type":20},"2027-01-02",{"name":41,"class":42},"Paul Kim","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100599072","phase-2-valganciclovir-vs-letermovir-for-cmv-prophylaxis-in-heart-transplant-100599072","NCT07079735","Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant","VALganciclovir vs. LETermovir for Primary Prevention of CMV in Moderate to High-Risk Heart Transplant Recipients (The VALET-CMV Study)","VALET-CMV","Inclusion Criteria:\n\nPatients who are \\>18 years of age who have received a heart transplant and have not started their CMV prophylaxis regimen will be included.\n\nExclusion Criteria:\n\nHistory of or suspected CMV disease within 6 months prior is excluded.","99 Years",{"count":54,"type":20},150,[56,57],"PHASE2","PHASE3","The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.",[60,61,26],"CMV Viremia","Heart Transplant Infection","2025-09-22",{"date":64,"type":35},"2025-09-25",{"date":66,"type":35},"2025-09-12",{"date":68,"type":20},"2029-01-17",{"name":70,"class":42},"Columbia University",2,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":83,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":43},"100550905","brazilian-clinical-registry-of-heart-transplantation-100550905","NCT06453148","Brazilian Clinical Registry of Heart Transplantation","Prospective Clinical Registry of Heart Transplant Patients in Brazil","HESTIA","Inclusion Criteria:\n\n* Patients over 18 years old;\n* Heart Transplantation within 30 days of both sexes;\n\nExclusion Criteria:\n\n* Refusal to provide consent for the study;\n* In the judgment of the local investigator, any difficulty accessing follow-up visits","75 Years",{"count":82,"type":20},730,"3 Years","OBSERVATIONAL","Prospective cohort clinical study, registry-based, multicenter, national, with the consecutive inclusion of patients with a history of Heart Transplantation in Brazil. The clinical registry will involve the participation until 25 centers. Patients will be included up to 30 days after Heart Transplant surgery and will be followed for one year. Laboratory tests and clinical parameters wil be collected in two clinical visits (6mo and 12 mo). The outcomes evaluate will be the total hospitalizations and all-cause death. It is expected to include 730 patients with a 12-month follow-up from the day of the transplant surgery. The findings of the HESTIA Registry may guide the management of post-heart transplant patients, aiming at reducing morbidity and mortality within 12 months after heart transplant surgery.",[26,87],"Heart Transplant","NOT_YET_RECRUITING","2024-06-07",{"date":91,"type":35},"2024-06-11",{"date":93,"type":20},"2024-08-25",{"date":95,"type":20},"2027-08-25",{"name":97,"class":42},"Hospital Israelita Albert Einstein",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":107,"conditions":108,"keywords":109,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":43},"100515651","a-clinical-study-of-association-between-postoperative-dyslipidemia-and-organ-rejection-in-transplant-patients-100515651","NCT05994274","A Clinical Study of Association Between Postoperative Dyslipidemia and Organ Rejection in Transplant Patients","A Prospective Clinical Study of Association Between Postoperative Dyslipidemia and Organ","Inclusion Criteria:\n\n* After heart transplantation\n* Age ≥ 18\n* Disease duration: symptomatic heart failure ≥ 6 months prior to screening date\n* The patient's informed consent\n\nExclusion Criteria:\n\n* Refusal of the patient to provide consent\n* Suspected poor capability to follow instructions and cooperate\n* Another life-threatening disease with poor prognosis (survival less than 2 years)\n* Participation in any other clinical study within less than 30 days prior to screening date",{"count":106,"type":20},80,"Abnormal lipid metabolism is a common complication after organ transplantation, with pathological changes in lipid parameters occurring in approximately 60-80% of cardiac transplant recipients receiving triple immunotherapy with cyclosporine, imid azathioprine, and methylprednisolone. With the significant increase in long-term survival and increasing age of transplant patients, atherosclerotic cardiovascular diseases, such as those caused by dyslipidemia, have become a major cause of transplant organ failure and recipient death. However, the causes of dyslipidemia after organ transplantation, as well as the effects and mechanisms of dyslipidemia on transplant rejection, are unknown.\n\nPrevious studies have found that 1. increased lipid levels occur in recipients after heart transplantation; 2. during rejection, hepatic PCSK9 expression is increased in recipients; 3. a high-fat environment increases the immunoreactivity of human peripheral blood lymphocytes. It is suggested that PCSK9-lipid disorder-immune cell interactions may be associated with the development of transplant rejection.\n\nIn this project, we propose to (1) establish a long-term follow-up system for postoperative cardiac transplantation patients in our department to track the characteristics of lipid changes in transplantation patients, to clarify the link between dyslipidemia and rejection, and to provide a strong evidence-based medical basis for the management of lipids during the perioperative period and in the postoperative period; (2) expand the dimensions of lipid-related assays under the support of the above system, and to incorporate transcriptomic, proteomic, and metabolomic research methods to elucidate transplantation rejection in a multidimensional manner. (ii) Expanding the dimensions of lipid-related assays to include transcriptomic, proteomic, and metabolomic studies to elucidate the relationship between PCSK9 and dyslipidemia in transplant patients; (iii) Adopting single-cell sequencing technology to deeply reveal the potential mechanism by which changes in lipids affect T-cell-mediated rejection of cardiac transplants. The mechanism of T-cell-mediated cardiac transplantation rejection is revealed by single-cell sequencing.",[26],[110,111,112,113,114],"heart transplantation","Macrophages","Fatty acid","PCSK9","Lipid metabolism","2023-08-08",{"date":117,"type":35},"2023-08-16",{"date":119,"type":20},"2023-12",{"date":121,"type":20},"2027-12",{"name":123,"class":42},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology"]